Healthcare: biotech cluster Atlanpole Biotherapies working to build French sovereignty

#Biotherapies #Updates&co
© National Cancer Institute

Located in Atlantic France, Atlanpole Biotherapies is one of the most attractive and dynamic clusters for the development of biotechnologies in France. Its biotech companies are experiencing strong growth but have to find ways to stimulate their innovation strategies. 

Members of the Atlanpole Biotherapies cluster have been working on the front line since the beginning of the current health crisis, whether in testing, vaccines, treatments or patient healthcare. Those companies raised €300,000 in six years and aim to build French sovereignty in terms of healthcare and therapies.

An exponentially growing cluster in the Atlantic France region

Atlanpole Biotherapies is an interregional competitiveness cluster that counts on 220 members, 32 of whom have recently joined in 2021. Those companies are based in the Atlantic France region, Brittany and Centre-Val-de-Loire. The members are involved in various fields such as radiopharmaceuticals, immunotherapeutics, regenerative medicine, digital technologies for innovative therapies and nutrition. 

In order to build French sovereignty that has been proved to be lacking during the pandemic, the French government launched the programme France Relance. 11 out of 50 France Relance winning projects in the healthcare sector are run by members of Atlanpole Biotherapies. The crisis has also highlighted the ability of those companies to work on vaccines and anti-Covid therapies: GoLiver, Clean Cells, AlgoSource, Naogen Pharma, NG Biotech, etc.

Financing challenges and constraints

Nevertheless, the cluster pointed out the financing challenges and constraints of the health research sector during the 2021 General Assembly of Atlanpole Biotherapies. The Atlantic France regional council is currently exploring solutions to tackle these financing issues.

In France, companies can access funding of up to €10 million. The testing of treatments on humans, however, is on another level, with far higher financing requirements (between €50 million and €100 million) that are not easily available to business entrepreneurs.

Maryvonne Hiance, Vice-president of the cluster Atlanpole Biotherapies, Vice-president & Director of strategy at OSE Immunotherapeutics.

Watch also